既往TP53克隆性造血变异与卢卡帕利治疗高级别卵巢癌后继发髓系肿瘤风险
该回顾性遗传关联研究分析了ARIEL2和ARIEL3研究中1052例高级别卵巢癌患者,发现22例(2.1%)发生治疗相关髓系肿瘤(t-MN),且t-MN与既往铂类暴露时间更长相关。
要点
- 卢卡帕利治疗高级别卵巢癌后t-MN发生率约2.1%,与既往铂类暴露时间更长相关。
- 治疗前TP53 CHIP变异(VAF≥1%)与卢卡帕利后t-MN风险相关,且变异在发生t-MN者中扩增。
核心结论
- 既往TP53 CHIP变异可能与卢卡帕利治疗后发生t-MN相关。
研究设计与样本
- 回顾性遗传关联研究,使用ARIEL2(n=491)和ARIEL3(n=561)研究中卢卡帕利治疗前采集的外周血细胞样本。
- 共1052例患者纳入分析,其中20例发生t-MN者为病例,随机选取44例未发生t-MN者为对照,进行靶向二代测序检测CHIP变异。
- 对ARIEL2中可获得的治疗期间和治疗结束时样本进行纵向分析。
主要发现
- 1052例患者中22例(2.1%)发生t-MN。
临床怎么用
- 对于接受卢卡帕利治疗的高级别卵巢癌患者,治疗前可考虑检测TP53 CHIP变异以识别t-MN高风险人群。
- 既往铂类暴露时间较长且携带TP53 CHIP变异的患者,应加强血液学监测。
局限性
- 回顾性研究设计,病例对照样本量较小(20例病例和44例对照)。
- 仅分析10个预设CHIP相关基因,可能遗漏其他相关变异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: A total of 1% to 3% of patients treated with a poly(adenosine diphosphate-ribose) polymerase inhibitor for high-grade ovarian cancer (HGOC) develop therapy-related myeloid neoplasms (t-MNs), which are rare but often fatal conditions. Although the cause of these t-MNs is unknown, clonal hematopoiesis of indeterminate potential (CHIP) variants can increase the risk of primary myeloid malignant neoplasms and are more frequent among patients with solid tumors. OBJECTIVES: To examine whether preexisting CHIP variants are associated with the development of t-MNs after rucaparib treatment and how these CHIP variants are affected by treatment. DESIGN, SETTING, AND PARTICIPANTS: This retrospective genetic association study used peripheral blood cell (PBC) samples collected before rucaparib treatment from patients in the multicenter, single-arm ARIEL2 (Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer) (n = 491; between October 30, 2013, and August 9, 2016) and the multicenter, placebo-controlled, double-blind ARIEL3 (Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer) (n = 561; between April 7, 2014, and July 19, 2016), which tested rucaparib as HGOC therapy in the treatment and maintenance settings, respectively. The follow-up data cutoff date was September 1, 2019. Of 1052 patients in ARIEL2 and ARIEL3, PBC samples from 20 patients who developed t-MNs (cases) and 44 randomly selected patients who did not (controls) were analyzed for the presence of CHIP variants using targeted next-generation sequencing. Additional longitudinal analysis was performed on available ARIEL2 samples collected during treatment and at the end of treatment. MAIN OUTCOMES AND MEASURES: Enrichment analysis of preexisting variants in 10 predefined CHIP-associated genes in cases relative to controls; association with clinical correlates. RESULTS: Among 1052 patients (mean [SE] age, 61.7 [0.3] years) enrolled and dosed in ARIEL2 and ARIEL3, 22 (2.1%) developed t-MNs. The t-MNs were associated with longer overall exposure to prior platinum therapies (13.2 vs 9.0 months in ARIEL2, P = .04; 12.4 vs 9.6 months in ARIEL3, P = .003). The presence of homologous recombination repair gene variants in the tumor, either germline or somatic, was associated with increased prevalence of t-MNs (15 [4.1%] of 369 patients with HGOC associated with an HRR gene variant vs 7 [1.0%] of 683 patients with wild-type HGOC, P = .002). The prevalence of preexisting CHIP variants in TP53 but not other CHIP-associated genes at a variant allele frequency of 1% or greater was significantly higher in PBCs from cases vs controls (9 [45.0%] of 20 cases vs 6 [13.6%] of 44 controls, P = .009). TP53 CHIP was associated with longer prior exposure to platinum (mean 14.0 months of 15 TP53 CHIP cases vs 11.1 months of 49 non-TP53 CHIP cases; P = .02). Longitudinal analysis showed that preexisting TP53 CHIP variants expanded in patients who developed t-MNs. CONCLUSIONS AND RELEVANCE: The findings of this genetic association study suggest that preexisting TP53 CHIP variants may be associated with t-MNs after rucaparib treatment.
引用
- Kwan TT, Oza AM, Tinker AV, et al. Preexisting TP53-Variant Clonal Hematopoiesis and Risk of Secondary Myeloid Neoplasms in Patients With High-grade Ovarian Cancer Treated With Rucaparib. JAMA Oncol. 2021. PMID: 34647981. doi:10.1001/jamaoncol.2021.4664
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。